267 related articles for article (PubMed ID: 22583147)
1. Epidemiology and management of hypertension in the Hispanic population: a review of the available literature.
Guzman NJ
Am J Cardiovasc Drugs; 2012 Jun; 12(3):165-78. PubMed ID: 22583147
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcomes in hypertensive patients of Hispanic descent.
Aranda JM; Calderon R; Aranda JM
Prev Cardiol; 2008; 11(2):116-20. PubMed ID: 18401240
[TBL] [Abstract][Full Text] [Related]
3. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension.
Chen R; Yang J; Gao X; Ding X; Yang Y; Shen Y; He C; Xiang H; Ke J; Yuan F; Cheng R; Lv H; Li P; Zhang L; Liu C; Tan H; Huang L
J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1974-1983. PubMed ID: 33006442
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
da Silva PM
Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
[TBL] [Abstract][Full Text] [Related]
5. Clinical role of direct renin inhibition in hypertension.
Taylor AA; Pool JL
Am J Ther; 2012 May; 19(3):204-10. PubMed ID: 21317620
[TBL] [Abstract][Full Text] [Related]
6. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
7. A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model.
Hallow KM; Lo A; Beh J; Rodrigo M; Ermakov S; Friedman S; de Leon H; Sarkar A; Xiong Y; Sarangapani R; Schmidt H; Webb R; Kondic AG
Am J Physiol Regul Integr Comp Physiol; 2014 May; 306(9):R647-62. PubMed ID: 24500431
[TBL] [Abstract][Full Text] [Related]
8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
9. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
Ferrario CM
Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering.
Ismail H; Mitchell R; McFarlane SI; Makaryus AN
Curr Diab Rep; 2010 Feb; 10(1):32-6. PubMed ID: 20425064
[TBL] [Abstract][Full Text] [Related]
11. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
12. Hypertension and antihypertensive therapy in Hispanics and Mexican Americans living in the United States.
Ventura H; Piña IL; Lavie CJ
Postgrad Med; 2011 Nov; 123(6):46-57. PubMed ID: 22104453
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
14. Race, obesity, and the renin-angiotensin-aldosterone system: treatment response in children with primary hypertension.
South AM; Arguelles L; Finer G; Langman CB
Pediatr Nephrol; 2017 Sep; 32(9):1585-1594. PubMed ID: 28411317
[TBL] [Abstract][Full Text] [Related]
15. Which is the optimal antihypertensive combination in different diseases, a renin- angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker?
Riva N; Lip GY
Curr Pharm Des; 2013; 19(21):3753-65. PubMed ID: 23286431
[TBL] [Abstract][Full Text] [Related]
16. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics, treatment patterns and outcomes of Hispanic hypertensive patients.
Campbell PT; Krim SR; Lavie CJ; Ventura HO
Prog Cardiovasc Dis; 2014; 57(3):244-52. PubMed ID: 25537632
[TBL] [Abstract][Full Text] [Related]
18. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
Trials; 2015 Dec; 16():581. PubMed ID: 26686682
[TBL] [Abstract][Full Text] [Related]
19. The impact of ethnicity on response to antihypertensive therapy.
Jamerson K; DeQuattro V
Am J Med; 1996 Sep; 101(3A):22S-32S. PubMed ID: 8876472
[TBL] [Abstract][Full Text] [Related]
20. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
